ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare DelCOA Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FDEHHYPOTHETICAL MODEL
Since ’99
+127%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Dec 2021
placeholder
Full Sharpe
0.24
Ann. Return (LS)
5.4%
Ann. Volatility
22.6%
Max Drawdown
-65.6%
Test Sharpe ’19–26
-0.61
Test FF5 α (ann.)
-10.9%
vs Fama-French 5
Test FF5 α t-stat
-1.69
not significant
Monthly turnover
19%
of the long leg, per rebalance
Cumulative return (LS)
127%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.60
what this fund holds
Long leg ann. return
13.9%
buyable, long-only
Long-short Sharpe
0.24
requires shorting
Bottom bucket ann. return
8.5%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
22.74%
2CI
CIGNA GROUPHealthcare$74.45B
13.65%
3RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
7.26%
4CNC
CENTENE CORPHealthcare$32.81B
6.01%
5DXCM
DEXCOM INCHealthcare$29.58B
5.42%
6MRNA
MODERNA INCHealthcare$24.53B
4.50%
7UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
4.17%
8BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
2.51%
9MOH
MOLINA HEALTHCARE INCHealthcare$11.74B
2.15%
10BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
2.11%
11CYTK
CYTOKINETICS INCHealthcare$9.98B
1.83%
12CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
1.78%
13HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
1.69%
14PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
1.66%
15ALKS
ALKERMES PLCHealthcare$8.79B
1.61%
16SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
1.16%
17ERAS
ERASCA INCHealthcare$5.96B
1.09%
18DFTX
DEFINIUM THERAPEUTICS INCHealthcare$4.83B
0.89%
19VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
0.79%
20ICUI
ICU MEDICAL INCHealthcare$3.94B
0.72%
21DOCS
DOXIMITY INCHealthcare$3.94B
0.72%
22RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
0.70%
23DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
0.68%
24RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.63%
25IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.58%
26RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.53%
27CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.51%
28VERA
VERA THERAPEUTICS INCHealthcare$2.76B
0.51%
29IMNM
IMMUNOME INCHealthcare$2.53B
0.46%
30PGNY
PROGYNY INCHealthcare$2.50B
0.46%
31NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.44%
32BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.43%
33AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.43%
34BHVN
BIOHAVEN LTDHealthcare$2.32B
0.43%
35IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
0.41%
36SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.41%
37AGL
AGILON HEALTH INCHealthcare$2.17B
0.40%
38CDNA
CAREDX INCHealthcare$2.05B
0.38%
39SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.37%
40AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.36%
41NVCR
NOVOCURE LTDHealthcare$1.84B
0.34%
42SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.33%
43ZYME
ZYMEWORKS INCHealthcare$1.77B
0.32%
44ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.31%
45FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.31%
46INVA
INNOVIVA INCHealthcare$1.60B
0.29%
47VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.29%
48NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.29%
49INSP
INSPIRE MEDICAL SYSTEMS INCHealthcare$1.46B
0.27%
50MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.27%
51SDGR
SCHRODINGER INCHealthcare$1.14B
0.21%
52EYPT
EYEPOINT INCHealthcare$1.12B
0.20%
53PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.18%
54KURA
KURA ONCOLOGY INCHealthcare$964M
0.18%
55ANNX
ANNEXON INCHealthcare$950M
0.17%
56REPL
REPLIMUNE GROUP INCHealthcare$859M
0.16%
57BBNX
BETA BIONICS INCHealthcare$771M
0.14%
58AURA
AURA BIOSCIENCES INCHealthcare$723M
0.13%
59SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.13%
60EVH
EVOLENT HEALTH INCHealthcare$654M
0.12%
61ACHV
ACHIEVE LIFE SCIENCES INCHealthcare$644M
0.12%
62NGNE
NEUROGENE INCHealthcare$590M
0.11%
63WEAV
WEAVE COMMUNICATIONS INCHealthcare$575M
0.11%
64ARVN
ARVINAS INCHealthcare$517M
0.09%
65RGNX
REGENXBIO INCHealthcare$511M
0.09%
66SGMT
SAGIMET BIOSCIENCES INCHealthcare$479M
0.09%
67CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.08%
68ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.07%
69EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.07%
70STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.07%
71UPB
UPSTREAM BIO INCHealthcare$382M
0.07%
72ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.07%
73VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.06%
74LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.06%
75FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.06%
76TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.05%
77TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.05%
78ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.04%
79SPOK
SPOK HOLDINGS INCHealthcare$222M
0.04%
80KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.04%
81KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.04%
82AMWL
AMERICAN WELL CORPHealthcare$199M
0.04%
83PDEX
PRO DEX INCHealthcare$183M
0.03%
84ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.03%
85RCEL
AVITA MEDICAL INCHealthcare$157M
0.03%
86PMN
PROMIS NEUROSCIENCES INCHealthcare$136M
0.02%
87AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.02%
88JYNT
JOINT CORPHealthcare$127M
0.02%
89SPRB
SPRUCE BIOSCIENCES INCHealthcare$120M
0.02%
90RLYB
RALLYBIO CORPHealthcare$87M
0.02%
91ACET
ADICET BIO INCHealthcare$76M
0.01%
92ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.01%
93MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.01%
94EXOZ
EXOZYMES INCHealthcare$51M
0.01%
95TIL
INSTIL BIO INCHealthcare$50M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $545.49B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
48%5
12%6
25%11
3%8
6%13
2%6
1%21
1%7
1%8

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 92% toward Large, 38% toward Growth. +3% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt92% → Large
SmallLarge
Value ↔ growth tilt38% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    69.9%
    Margin
    -5.1%
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.3 (95% CI 0.8-1.6)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
12.3%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.28x
within
parametric
1.47x
within
cornish fisher
2.48x
over · unreliable

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2005
Before publication (pre-2005)
0.62
Sharpe · 22.3% p.a.
January 1999December 2005 · 84 mo
Since publication
-0.02
Sharpe · -0.4% p.a.
January 2006July 2026 · 247 mo
Change in Sharpe−0.65the return reversed sign — the published edge now runs the other way

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
58%
15 of 26 3-year windows made money
Worst window
-1.03
Sharpe, January 2023 – December 2025
January 1999July 2026
Median Sharpe
0.21
Dispersion
0.74
Best window
1.55

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.64.7%-2.0%
3 yearsp.a.10.4%-13.4%
5 yearsp.a.2.3%-7.8%
10 yearsp.a.6.1%-6.2%
Since inceptionp.a.12.0%3.0%
Calendar years
YearLong legLong-short
20267 mo19.1%3.9%
202523.5%-8.1%
2024-7.3%-28.0%
20234.7%-9.1%
2022-13.8%3.3%
2021-6.1%-17.3%
20207.0%-27.9%
201919.9%-0.9%
2018-1.1%6.9%
201732.7%22.5%
2016-2.7%17.5%
201510.5%5.8%
201425.5%-2.0%
201343.2%-1.6%
201234.1%24.4%
201113.1%10.0%
201016.5%12.4%
200911.1%-10.9%
2008-18.2%2.8%
20071.3%-21.4%
200617.0%9.4%
2005-3.0%-11.1%
2004-6.3%-16.1%
200380.3%57.0%
2002-38.5%-14.0%
200119.7%57.1%
200079.3%27.9%
199946.5%54.7%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FDEH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-12-06 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$545.49B

Methodology

The Foundry Healthcare DelCOA Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a DelCOA signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.